Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Breast Cancer

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 86 articles: HTML format

Single Articles

January 2026
1. NARDIN S, Bruzzone M, Arecco L, Chiappe E, et al
   Comparison of suboptimal versus adequate ovarian function suppression in premenopausal women with early breast cancer treated with adjuvant endocrine therapy: An exploratory analysis of two prospective studies.
   Eur J Cancer. 2026;236:116266.
   PubMed     Abstract available
   
   
   
2. ARISTEI C, Tomatis M, Ponti A, Marotti L, et al
   Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database.
   Eur J Cancer. 2026;236:116259.
   PubMed     Abstract available
   
   
   
3. NYBACK S, Poromaa IS, Lindman H, Hirschberg AL, et al
   Vaginal tamoxifen - A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen.
   Eur J Cancer. 2026;236:116261.
   PubMed     Abstract available
   
   
   
4. SPATA A, Ribeiro JM, Vigneri P, Zambelli A, et al
   Comprehensive review of pregnancy associated breast cancer: Clinical features, molecular characteristics and novel therapies.
   Eur J Cancer. 2026;235:116230.
   PubMed     Abstract available
   
   
   
5. VALDERRAMA NF, Morel LO, Mweze DT, Derangere V, et al
   Chemo-prAIdict Breast: A deep learning solution for predicting residual disease on biopsies of breast cancer patients treated with neoadjuvant chemotherapy.
   Eur J Cancer. 2026;234:116222.
   PubMed     Abstract available
   
   
   
6. YAN Y, Xue X, Xie J, Liu J, et al
   Prediction of HER2 changes post-neoadjuvant therapy based on fusion of ultrasound radiomics and clinicopathological features empowered by explainable AI: A multicenter study.
   Eur J Cancer. 2026;232:116158.
   PubMed     Abstract available
   
   
   December 2025
7. DIECI MV, Vernaci G, Colangelo C, Bria E, et al
   PIK3CA mutations and first-line outcomes in endocrine-resistant HR+/HER2- metastatic breast cancer: A multicentric real-world study.
   Eur J Cancer. 2025;234:116194.
   PubMed     Abstract available
   
   
   
8. NICOLO E, Reduzzi C, Pierga JY, Gazzaniga P, et al
   International expert consensus on the clinical integration of circulating tumor cells in solid tumors.
   Eur J Cancer. 2025;231:116050.
   PubMed     Abstract available
   
   
   
9. BOUTEILLER F, Gourgou S, Bringuier M, Galvin A, et al
   Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort.
   Eur J Cancer. 2025;233:116166.
   PubMed     Abstract available
   
   
   
10. BORREGO MR, Lopez-Bravo DP, Vila MM, Perez-Garcia JM, et al
    Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study.
    Eur J Cancer. 2025;233:116161.
    PubMed     Abstract available
    
    
    
11. PENAULT-LLORCA F, Lusque A, Filleron T, Tran K, et al
    Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score(R) in node-positive breast cancer: Independent validation in the PACS-01 trial.
    Eur J Cancer. 2025;233:116152.
    PubMed     Abstract available
    
    
    November 2025
12. ZHANG R, Li H, Ding L, Liu H, et al
    Subvisual imaging signals as biomarkers of impending lung metastasis: A multicenter pan-cancer study.
    Eur J Cancer. 2025;230:116056.
    PubMed     Abstract available
    
    
    
13. ZUO H, Vaihenberg E, Singh A, Bal G, et al
    Response to letter Re: Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation.
    Eur J Cancer. 2025;232:116113.
    PubMed    
    
    
    
14. WOOLPERT KM, Collin LJ, Cronin-Fenton DP
    Letter Re: Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation.
    Eur J Cancer. 2025;232:116112.
    PubMed    
    
    
    
15. BUONAIUTO R, Martorana F, Marino P, Mangiacotti F, et al
    Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer.
    Eur J Cancer. 2025;232:116102.
    PubMed     Abstract available
    
    
    
16. PUJOL P, Roca L, Lortholary A, Lasset C, et al
    Letrozole to prevent breast cancer in postmenopausal women with BRCA1/2 mutations (LIBER study).
    Eur J Cancer. 2025;231:116101.
    PubMed     Abstract available
    
    
    
17. RASSY E, Delaloge S, Karimi M, Truong T, et al
    Evaluating breast cancer screening consortium and MammoRisk plus polygenic risk score 313 for breast cancer risk prediction in UK Biobank.
    Eur J Cancer. 2025;231:116096.
    PubMed     Abstract available
    
    
    October 2025
18. SPOOR DS, Boekel NB, Leeuwen FEV, Russell N, et al
    Predicting acute coronary events after breast cancer radiotherapy: Integrating baseline cardiovascular risk, systemic therapy, and cardiac radiation dose in the MEDIRAD BRACE study.
    Eur J Cancer. 2025;231:116055.
    PubMed     Abstract available
    
    
    
19. WORTELBOER N, Kent S, Konings IR, van Ommen-Nijhof A, et al
    Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial.
    Eur J Cancer. 2025;231:116051.
    PubMed     Abstract available
    
    
    
20. BELCASTRO E, Marletta S, Tornabene I, Cinacchi P, et al
    MTClin: Integrating MammaTyper(R) to predict neoadjuvant therapy response in HER2+?breast cancer.
    Eur J Cancer. 2025;230:116049.
    PubMed     Abstract available
    
    
    
21. SALFI G, Olivier T
    When suboptimal post-protocol care in oncology trials is rewarded.
    Eur J Cancer. 2025;228:115702.
    PubMed     Abstract available
    
    
    September 2025
22. ZHANG S, Sun T, Wang X, Yan M, et al
    Efficacy and safety of MRG002 monotherapy in treating patients with locally advanced or metastatic breast cancer with low HER2 expression: A multi-center, non-randomized, open-label phase II clinical trial.
    Eur J Cancer. 2025;230:115794.
    PubMed     Abstract available
    
    
    
23. ZUO H, Vaihenberg E, Singh A, Bal G, et al
    Response to Letter Re: Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation.
    Eur J Cancer. 2025;229:115781.
    PubMed    
    
    
    
24. MOUSTAQUIM J, van Wonderen GE, van Geel JJL, van Kruchten M, et al
    Comparative analysis of FES-PET/CT and FDG-PET/CT in patients with ER-positive metastatic invasive lobular breast cancer.
    Eur J Cancer. 2025;229:115792.
    PubMed     Abstract available
    
    
    
25. HANVIC B, Joureau-Chabert A, Ouldbey Y, Toussaint P, et al
    Compression therapy with surgical gloves compared to cold therapy with frozen gloves in preventing paclitaxel-induced peripheral neuropathy: Results from the prospective ELEGANT trial in patients with breast cancer.
    Eur J Cancer. 2025;229:115791.
    PubMed     Abstract available
    
    
    
26. WANG ZN, Tian GH, Ding JR, Lin Y, et al
    Acupuncture effect on brain default mode network connectivity in breast cancer patients with hot flashes: A randomized controlled trial.
    Eur J Cancer. 2025;229:115785.
    PubMed     Abstract available
    
    
    
27. ALTUNDAG K
    Letter Re: Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation.
    Eur J Cancer. 2025;229:115780.
    PubMed    
    
    
    
28. HAYASHI T, Ogita M, Kakegawa R, Kikawa Y, et al
    Comparison of hypofractionation and conventional fractionation in postmastectomy radiotherapy after immediate breast reconstruction: A systematic review and meta-analysis of complications.
    Eur J Cancer. 2025;227:115669.
    PubMed     Abstract available
    
    
    
29. AUTIER P, Jorgensen KJ, Stovring H
    Evaluation of screening mammography effectiveness: The IARC recommendations of 2015 need revision.
    Eur J Cancer. 2025;227:115657.
    PubMed     Abstract available
    
    
    August 2025
30. VALENZA C, Curigliano G
    Positioning oral selective estrogen receptor degraders in patients with metastatic breast cancer.
    Eur J Cancer. 2025;228:115739.
    PubMed     Abstract available
    
    
    
31. ALPERT A, Shirron N, Shirman Y, Goshen-Lago T, et al
    Deciphering the proteomic landscape of pregnancy-associated colorectal cancer.
    Eur J Cancer. 2025;228:115718.
    PubMed     Abstract available
    
    
    
32. MICHEL LL, Ziegler P, Kreis P, Hartkopf AD, et al
    Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer.
    Eur J Cancer. 2025;227:115689.
    PubMed     Abstract available
    
    
    July 2025
33. ZUO H, Vaihenberg E, Singh A, Bal G, et al
    Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation.
    Eur J Cancer. 2025;227:115665.
    PubMed     Abstract available
    
    
    
34. GIORGI ROSSI P, Venturelli F
    Letter Re: Evaluation of screening mammography effectiveness: The IARC recommendations of 2015 need revision: Observational studies on breast cancer screening: different perspectives and questions require different approaches.
    Eur J Cancer. 2025;227:115659.
    PubMed    
    
    
    
35. DI MICCO R, Hartmann S, Banys-Paluchowski M, de Boniface J, et al
    Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients - Results from the prospective AXSANA registry trial.
    Eur J Cancer. 2025;226:115607.
    PubMed     Abstract available
    
    
    June 2025
36. KNAUER M, Egle D, Hayoz S, Savolt A, et al
    Genomic profiling of primary tumor and lymph node metastasis in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
    Eur J Cancer. 2025;225:115585.
    PubMed     Abstract available
    
    
    May 2025
37. RUGGIERO E, Sharma S, Di Castelnuovo A, Costanzo S, et al
    Olive oil consumption and risk of breast cancer: Prospective results from the Moli-sani Study, and a systematic review of observational studies and randomized clinical trials.
    Eur J Cancer. 2025;224:115520.
    PubMed     Abstract available
    
    
    
38. DI MICCO R, Botteri E, Canevari C, Gallivanone F, et al
    [(18)F]FDG PET/MRI vs sentinel node biopsy for axillary staging of early breast cancer patients. A prospective single-arm trial.
    Eur J Cancer. 2025;224:115519.
    PubMed     Abstract available
    
    
    
39. DAUCCIA C, Alice Franzoi M, Martel S, Agbor-Tarh D, et al
    Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial.
    Eur J Cancer. 2025;223:115489.
    PubMed     Abstract available
    
    
    
40. VAN KESSEL E, Woerdman N, Pluim D, Kerklaan BM, et al
    Added prognostic value of circulating tumor cell numbers in CSF of patients with leptomeningeal metastasis from epithelial tumors.
    Eur J Cancer. 2025;220:115377.
    PubMed     Abstract available
    
    
    April 2025
41. DING N, Hermans KEPE, van Nijnatten TJA, Engelen SME, et al
    Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: A population-based cohort study of systemically treated patients.
    Eur J Cancer. 2025;222:115475.
    PubMed     Abstract available
    
    
    
42. BIGANZOLI G, Isnaldi E, Richard F, Marano G, et al
    Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial.
    Eur J Cancer. 2025;222:115438.
    PubMed     Abstract available
    
    
    
43. MAGATON IM, Blondeaux E, Hamy AS, Linn S, et al
    Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study.
    Eur J Cancer. 2025;222:115434.
    PubMed     Abstract available
    
    
    
44. DE PLACIDO P, Di Rienzo R, Pietroluongo E, Martinelli C, et al
    Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study.
    Eur J Cancer. 2025;221:115409.
    PubMed     Abstract available
    
    
    
45. MIYAWAKI IA, Banerjee I, Batalini F, Campello Jorge CA, et al
    Global disparities in artificial intelligence-based mammogram interpretation for breast cancer: A scientometric analysis of representation, trends, and equity.
    Eur J Cancer. 2025;220:115394.
    PubMed     Abstract available
    
    
    March 2025
46. BEDARD PL, Jhaveri KL, Accordino MK, Cervantes PA, et al
    Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study.
    Eur J Cancer. 2025;221:115397.
    PubMed     Abstract available
    
    
    
47. BOTTOSSO M, Sandoval RL, Verret B, Polidorio N, et al
    Corrigendum to "HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome" [Eur J Cancer 211 (2024) 114307].
    Eur J Cancer. 2025 Mar 18:115370. doi: 10.1016/j.ejca.2025.115370.
    PubMed    
    
    
    
48. SIITONEN H, Joensuu J, Savolainen-Peltonen H, Gissler M, et al
    Update of the impact of menopausal hormone therapy on breast cancer risk.
    Eur J Cancer. 2025;220:115340.
    PubMed     Abstract available
    
    
    February 2025
49. METZGER FILHO O, Cardoso F, Poncet C, Desmedt C, et al
    Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial.
    Eur J Cancer. 2025;217:115222.
    PubMed     Abstract available
    
    
    
50. GRIGUOLO G, Bottosso M, Crema A, Giarratano T, et al
    Exceptional responses to systemic treatment in metastatic breast cancer: clinical features and long-term outcomes.
    Eur J Cancer. 2025;219:115321.
    PubMed     Abstract available
    
    
    
51. STEGER K, Fiegl H, Feroz B, Leitner K, et al
    Differences in immunogenicity of TP53-mutated cancers with low tumor mutational burden (TMB) A study on TP53mut endometrial-, ovarian- and triple-negative breast cancer.
    Eur J Cancer. 2025;219:115320.
    PubMed     Abstract available
    
    
    January 2025
52. COTTU P
    Identifying and managing adverse prognosis biomarkers among advanced luminal breast cancer patients: What have we learned?
    Eur J Cancer. 2025 Jan 10:115228. doi: 10.1016/j.ejca.2025.115228.
    PubMed    
    
    
    
53. HART LL, Im SA, Tolaney SM, Campone M, et al
    Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials.
    Eur J Cancer. 2025;217:115225.
    PubMed     Abstract available
    
    
    
54. GIL QUESSEP E, van der Waal D, Peters J, Delaloge S, et al
    Subgroups varying in risk and density highlight the potential for stratified breast cancer screening.
    Eur J Cancer. 2025;217:115220.
    PubMed     Abstract available
    
    
    
55. TOLOSA P, Pascual T, Martinez-Saez O, Hernando C, et al
    Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study.
    Eur J Cancer. 2025 Jan 3:115219. doi: 10.1016/j.ejca.2024.115219.
    PubMed     Abstract available
    
    
    December 2024
56. DENNIS N, Dunton K, Livings C, Bogoeva N, et al
    Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial.
    Eur J Cancer. 2024;217:115192.
    PubMed     Abstract available
    
    
    
57. NEVEN P, Han S, Verhoeven D, Soubry A, et al
    Letter re: Higher relative survival in breast cancer patients treated in certified and high-volume breast cancer centres - A population-based study in Belgium.
    Eur J Cancer. 2024 Dec 14:115166. doi: 10.1016/j.ejca.2024.115166.
    PubMed    
    
    
    
58. LEROY R, Bourgeois J, Canon JL, Carly B, et al
    Response to letter entitled: Re: Higher relative survival in breast cancer patients treated in certified and high-volume breast cancer centres - A population-based study in Belgium.
    Eur J Cancer. 2024 Dec 9:115167. doi: 10.1016/j.ejca.2024.115167.
    PubMed    
    
    
    
59. MILANO M, Valenza C, Ferrari A, Gandini S, et al
    Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer.
    Eur J Cancer. 2024;215:115164.
    PubMed     Abstract available
    
    
    November 2024
60. MOLINELLI C, Bruzzone M, Blondeaux E, Ruelle T, et al
    The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study.
    Eur J Cancer. 2024;213:115113.
    PubMed     Abstract available
    
    
    
61. ANKERSMID JW, Drossaert CHC, Strobbe LJA, Hackert MQN, et al
    Shared decision-making supported by outcome information regarding surveillance after curative treatment for breast cancer: Results of the SHOUT-BC study.
    Eur J Cancer. 2024;213:115107.
    PubMed     Abstract available
    
    
    October 2024
62. LIVRAGHI L, Martella F, Ghilli M, Angiolini C, et al
    Prospective study on Oncotype DX(R) assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial.
    Eur J Cancer. 2024;213:115108.
    PubMed     Abstract available
    
    
    
63. VALENZA C, Trapani D, Zagami P, Antonarelli G, et al
    Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study.
    Eur J Cancer. 2024;213:115097.
    PubMed     Abstract available
    
    
    
64. ANTOINE A, Perol D, Robain M, Bachelot T, et al
    Assessing the real-world effectiveness of 8 major metastatic breast cancer drugs using target trial emulation.
    Eur J Cancer. 2024;213:115072.
    PubMed     Abstract available
    
    
    
65. LEE DW, Ryu HS, Nikas IP, Koh J, et al
    Immune marker expression and prognosis of early breast cancer expressing HER3.
    Eur J Cancer. 2024;213:115081.
    PubMed     Abstract available
    
    
    
66. VAN OMMEN-NIJHOF A, Steenbruggen TG, Wiersma TG, Balduzzi S, et al
    Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study.
    Eur J Cancer. 2024;213:115083.
    PubMed     Abstract available
    
    
    September 2024
67. GANNON MR, Dodwell D, Miller K, Medina J, et al
    Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: A national population-based cohort study using routine data.
    Eur J Cancer. 2024;211:114309.
    PubMed     Abstract available
    
    
    
68. BOTTOSSO M, Sandoval RL, Verret B, Polidorio N, et al
    HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome.
    Eur J Cancer. 2024;211:114307.
    PubMed     Abstract available
    
    
    
69. BOTTA L, Capocaccia R, Bernasconi A, Rossi S, et al
    Estimating cure and risk of death from other causes of cancer patients: EUROCARE-6 data on head & neck, colorectal, and breast cancers.
    Eur J Cancer. 2024;208:114187.
    PubMed     Abstract available
    
    
    
70. CHEN J, Yin Y, Li G, Tian H, et al
    Integrated nomogram to predict HER2 expression in breast tumor: Clinical, Ultrasound, and Photoacoustic imaging approaches.
    Eur J Cancer. 2024;209:114259.
    PubMed     Abstract available
    
    
    August 2024
71. STEVENTON L, Kipps E, Man KK, Roylance R, et al
    The impact of inter-cycle treatment delays on 5-year all-cause mortality in early-stage breast cancer: A retrospective cohort study.
    Eur J Cancer. 2024;210:114301.
    PubMed     Abstract available
    
    
    
72. DUBOEUF M, Amadou A, Coudon T, Grassot L, et al
    Long-term exposure to air pollution at residential and workplace addresses and breast cancer risk: A case-control study nested in the French E3N-Generations cohort from 1990 to 2011.
    Eur J Cancer. 2024;210:114293.
    PubMed     Abstract available
    
    
    July 2024
73. FASCHING PA, Hack CC, Nabieva N, Maass N, et al
    Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.
    Eur J Cancer. 2024;209:114239.
    PubMed     Abstract available
    
    
    
74. LEROY R, Silversmit G, Bourgeois J, De Gendt C, et al
    Higher relative survival in breast cancer patients treated in certified and high-volume breast cancer centres - A population-based study in Belgium.
    Eur J Cancer. 2024;210:114232.
    PubMed     Abstract available
    
    
    
75. DARBANDI MR, Darbandi M, Darbandi S, Bado I, et al
    Artificial intelligence breakthroughs in pioneering early diagnosis and precision treatment of breast cancer: A multimethod study.
    Eur J Cancer. 2024;209:114227.
    PubMed     Abstract available
    
    
    
76. MARTINS-BRANCO D, Nader-Marta G, Molinelli C, Ameye L, et al
    Response to letter re: Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis.
    Eur J Cancer. 2024;208:114195.
    PubMed    
    
    
    June 2024
77. HASLAM A, Ranganathan S, Prasad V, Olivier T, et al
    CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms.
    Eur J Cancer. 2024;207:114192.
    PubMed     Abstract available
    
    
    
78. CHEW SM, Ferraro E, Safonov A, Chen Y, et al
    Impact of cyclin dependent kinase 4/6 inhibitors on breast cancer brain metastasis outcomes.
    Eur J Cancer. 2024;207:114175.
    PubMed     Abstract available
    
    
    
79. IGNATIADIS M, Poulakaki F, Spanic T, Brain E, et al
    EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe.
    Eur J Cancer. 2024;207:114156.
    PubMed     Abstract available
    
    
    May 2024
80. HAN W, Zhang DD, Zhang YW, Shi LZ, et al
    Letter re: Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2024 May 22:114126. doi: 10.1016/j.ejca.2024.114126.
    PubMed    
    
    
    April 2024
81. GUERINI-ROCCO E, Bellerba F, Concardi A, Taormina SV, et al
    Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ.
    Eur J Cancer. 2024;203:114063.
    PubMed     Abstract available
    
    
    
82. COLOMBO I, Koster KL, Holer L, Haefliger S, et al
    TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
    Eur J Cancer. 2024;201:113588.
    PubMed     Abstract available
    
    
    
83. BARTELS SAL, van Olmen JP, Scholten AN, Bekers EM, et al
    Real-world data on malignant and borderline phyllodes tumors of the breast: A population-based study of all 921 cases in the Netherlands (1989 -2020).
    Eur J Cancer. 2024;201:113924.
    PubMed     Abstract available
    
    
    March 2024
84. ROUSSOT N, Constantin G, Desmoulins I, Bergeron A, et al
    Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
    Eur J Cancer. 2024;202:114037.
    PubMed     Abstract available
    
    
    
85. UNTCH M, Perol D, Mayer EL, Cortes J, et al
    Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis.
    Eur J Cancer. 2024;202:113977.
    PubMed     Abstract available
    
    
    November 2023
86. LIM JSJ, Ow SGW, Wong ALA, Lee MXW, et al
    Phase II study of trifluridine/tipiracil in metastatic breast cancers with or without prior exposure to fluoropyrimidines.
    Eur J Cancer. 2023;193:113311.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum